New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study - PubMed
a day ago
- #risk-stratification
- #PSMA-PET
- #prostate-cancer
- Study introduces new prostate cancer risk groups based on PSMA-PET (PPP3) for improved prognostication of 3-year, 5-year, and 7-year overall survival.
- International, retrospective, registry-based cohort study involving 11,154 patients from 35 sites across Europe, Asia, Australia, North America, and South America.
- Development and validation cohorts were created with median follow-up of 4.9 years.
- PPP3 nomograms showed high accuracy with C indices of 0.83 (visual) and 0.84 (quantitative), outperforming established clinical risk scores.
- Simplified risk-stratification table developed for easier clinical use.
- PROMISE and PPP3 assessments are freely available online for global implementation.
- Funding sources include German Research Foundation, Prostate Cancer Foundation, and pharmaceutical companies like Novartis and AstraZeneca.
- Multiple authors report conflicts of interest, including consulting fees, grants, and advisory roles with pharmaceutical companies.